Navigation Links
Stem cell patch may result in improved function following heart attack
Date:11/15/2010

CINCINNATIUniversity of Cincinnati (UC) researchers have found that applying a stem cell-infused patch together with overexpression of a specific cell instruction molecule promoted cell migration to damaged cardiac tissue following heart attack and resulted in improved function in animal models.

The researchers also found that function improved more so than when stem cells were directly injected in heart tissuea therapy that is being studied elsewhere.

These findings are being presented for the first time at the American Heart Association's Scientific Meeting in Chicago on Nov. 15.

Researchers in the department of pathology and laboratory medicine led by Yi-Gang Wang, PhD, found that when a tri-cell patch, made up of cardiomyocytes (to restore heart contractility), endothelial cells (to build new blood vessels) and embryonic fibroblasts (to provide support to the cell structure), was applied to the surface of the damaged area of the heart, better outcomes in overall heart function resulted.

"Following myocardial infarction, better known as heart attack, tissue becomes damaged and scarred, cardiomyocytes die and heart pump function is reduced," Wang says. "There are therapies being tested by other researchers where stem cells are injected directly into damaged heart muscle to see if contractile function can be restored.

"In our current study, we wanted to determine if the amplified instructions from overexpressed miR-29, a microRNA, in animal models would enhance the effectiveness of the cell patch by reducing barriers in the infarcted area, leading to enhanced regeneration of heart tissues and resulting in the restoration of heart function after myocardial infarction."

Researchers first generated cardiac progenitor cellscells that can become various cardiac tissue cell typesfrom induced pluripotent stem cells (iPSC). These stem cells can differentiate into any type of cell in the body and are artificially derived from non-pluripotent cells by inducing a forced expression of a number of desired genes.

The iPSC were then combined with specific heart tissue promoters to generate the desired cells. These cells were also labeled with green fluorescent protein (GFP) and firefly luciferase (a glowing laboratory reagent) to help with tracing cell migration and proliferation into the animal's system.

Researchers injected either the virus-mediated miR29b or a control material into the heart of the animal model and then experimentally induced a heart attack.

"These models allowed us to determine the possible benefits of miR29b and outcomes observed in two different control groups," Wang says.

Three days following the heart attack, researchers placed a cell patch on the damaged region and measured the expression of cardiac-related transcription factor A (a protein that binds to specific DNA sequences, controlling the movement of genetic information from DNA to mRNA), collagen levels in the damaged tissue and scar formation-related signaling pathways.

One month after the cell patch implantation, echocardiograms were performed to evaluate heart function.

"The mobilization of cells into the infarcted region of the heart was then analyzed by counting the number of GFP cells and by bioluminescence imaging (BLI) of cells with firefly luciferase, an imaging technology where the ongoing biological processes are visualized," Wang says.

Researchers found the number of GFP cells, BLI signals and heart function as a whole significantly increased in animals with the viral transfer that overexpressed miR-29b and were treated with the tri-cell patch.

"These findings show that an overexpression of miR-29 results in heart tissue changes that favor enhanced mobilization of desired cell types into infarct regions after heart attack, leading to improved heart function," he says. "Hopefully, one day such treatments will restore cardiac function in patients who have experienced a heart attack, leading to a longer and better quality of life."


'/>"/>

Contact: Katie Pence
katie.pence@uc.edu
513-558-4561
University of Cincinnati Academic Health Center
Source:Eurekalert

Related biology news :

1. New pump created for microneedle drug-delivery patch
2. Ocean stirring and plankton patchiness
3. Even small patches of urban woods are valuable for migrating birds
4. Ancient artifacts reveals as northern ice patches melt
5. Penn team uses self-assembly to make molecule-sized particles with patches of charge
6. Isolated forest patches lose species, diversity
7. Networks of small habitat patches can preserve urban biodiversity
8. Sweat it out: UH study examines ability of sweat patches to monitor bone loss
9. PDL BioPharma to Announce Third Quarter 2010 Financial Results on November 10, 2010
10. Aware, Inc. Reports Third Quarter 2010 Financial Results
11. Mathematical model may result in better environment measures for the Baltic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2017)... , Feb. 7, 2017   MedNet Solutions ... the entire spectrum of clinical research, is pleased to ... , its innovative, highly flexible and award winning ... customers. iMedNet is a proven Software-as-a-Service ... Electronic Data Capture (EDC), but also delivers an entire ...
(Date:2/6/2017)... , Feb. 6, 2017 According to ... are driving border authorities to continue to embrace ... there are 2143 Automated Border Control (ABC) eGates ... deployed at more than 163 ports of entry ... to 2016 achieving a combined CAGR of 37%. ...
(Date:2/2/2017)... 2017   TapImmune, Inc. (NASDAQ: ... in the development of innovative peptide and gene-based ... and metastatic disease, announced today it has successfully ... a second clinical lot of TPIV 200, the ... The manufactured vaccine product will be used to ...
Breaking Biology News(10 mins):
(Date:2/23/2017)...  Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing ... that Linda Marbán, Ph.D, president and chief executive officer, is ... Cowen and Company 37th Annual Health Care Conference ... Boston, MA 29th Annual ROTH ... pm ET) Dana Point, CA ...
(Date:2/23/2017)... DIEGO and SAN FRANCISCO ... a privately-held regenerative medicine company, and Beyond Type 1, ... with type 1 diabetes, today announced a grant from ... a functional cure for type 1 and other insulin-requiring ... ViaCyte has been developing innovative stem cell-derived cell replacement ...
(Date:2/22/2017)...  Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company ... products for companion animals, will host a live conference call ... discuss financial results from the fourth quarter and full year ... investors may access the audio webcast or use ... ...
(Date:2/22/2017)... ... February 22, 2017 , ... Park Systems , a leader in Atomic ... all SPIE attendees and Park customers on Feb. 27, 2017 from 12-2pm ... Jose Convention Center. The luncheon will feature a talk on Automated AFM for ...
Breaking Biology Technology: